VRI to raise $2.9 million
Tuesday, 30 March, 2004
VRI Biomedical has announced plans to raise up to AUD$2.9 million through a just completed share placement and a non-renounceable rights issue to be put towards production and marketing of the company's proTract probiotic products.
The recent placement of nearly 5 million shares at $0.16 per share to institutional investors has raised about $743,000 after costs, while the rights issue, which is fully underwritten, is expected to raise $2.1 million.
VRI has recently launched the proTract products for symptomatic relief of gastrointestinal disorders including irritable bowel syndrome and diarrhoea in Australian pharmacies and expects 3000 pharmacies to be carrying the products by June.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
